Incyte announces positive interim data from phase 2 trial of pemigatinib
Incyte announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma who failed at least one previous treatment. Interim study results demonstrated an ORR of 40 percent. October 21, 2018